Histogenics (HSGX) Misses Q4 EPS by 18c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Histogenics (HSGX) Misses Q4 EPS by 18c

Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016

March 16, 2017 6:30 AM EDT

NeoCart® Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 Strong Performance in all Areas of the Business in 2016 Financing Completed in the Third Quarter of 2016 Expected to Fund Company to Phase 3 Data Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) --  Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the year ended December 31, 2016. 

... More